Literature DB >> 32914330

Multidisciplinary management of acromegaly: A consensus.

Andrea Giustina1, Garni Barkhoudarian2, Albert Beckers3, Anat Ben-Shlomo4, Nienke Biermasz5, Beverly Biller6, Cesar Boguszewski7, Marek Bolanowski8, Jens Bollerslev9, Vivien Bonert4, Marcello D Bronstein10, Michael Buchfelder11, Felipe Casanueva12, Philippe Chanson13, David Clemmons14, Maria Fleseriu15, Anna Maria Formenti16, Pamela Freda17, Monica Gadelha18, Eliza Geer19, Mark Gurnell20, Anthony P Heaney21, Ken K Y Ho22, Adriana G Ioachimescu23, Steven Lamberts24, Edward Laws25, Marco Losa26, Pietro Maffei27, Adam Mamelak4, Moises Mercado28, Mark Molitch29, Pietro Mortini26, Alberto M Pereira5, Stephan Petersenn30, Kalmon Post31, Manuel Puig-Domingo32, Roberto Salvatori33, Susan L Samson34, Ilan Shimon35, Christian Strasburger36, Brooke Swearingen37, Peter Trainer38, Mary L Vance39, John Wass40, Margaret E Wierman41, Kevin C J Yuen42, Maria Chiara Zatelli43, Shlomo Melmed4.   

Abstract

The 13th Acromegaly Consensus Conference was held in November 2019 in Fort Lauderdale, Florida, and comprised acromegaly experts including endocrinologists and neurosurgeons who considered optimal approaches for multidisciplinary acromegaly management. Focused discussions reviewed techniques, results, and side effects of surgery, radiotherapy, and medical therapy, and how advances in technology and novel techniques have changed the way these modalities are used alone or in combination. Effects of treatment on patient outcomes were considered, along with strategies for optimizing and personalizing therapeutic approaches. Expert consensus recommendations emphasize how best to implement available treatment options as part of a multidisciplinary approach at Pituitary Tumor Centers of Excellence.

Entities:  

Keywords:  Acromegaly; Consensus; Medical therapy; Multidisciplinary management; Pituitary tumor centers of excellence; Radiotherapy; Surgery

Year:  2020        PMID： 32914330      PMCID： PMC7942783          DOI： 10.1007/s11154-020-09588-z

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


  109 in total

1.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

Authors:  P J Trainer; W M Drake; L Katznelson; P U Freda; V Herman-Bonert; A J van der Lely; E V Dimaraki; P M Stewart; K E Friend; M L Vance; G M Besser; J A Scarlett; M O Thorner; C Parkinson; A Klibanski; J S Powell; A L Barkan; M C Sheppard; M Malsonado; D R Rose; D R Clemmons; G Johannsson; B A Bengtsson; S Stavrou; D L Kleinberg; D M Cook; L S Phillips; M Bidlingmaier; C J Strasburger; S Hackett; K Zib; W F Bennett; R J Davis
Journal:  N Engl J Med       Date:  2000-04-20       Impact factor: 91.245

2.  Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.

Authors:  Hussain Alquraini; Maria Del Pilar Schneider; Beloo Mirakhur; Ariel Barkan
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

Review 3.  Place of cabergoline in acromegaly: a meta-analysis.

Authors:  Laure Sandret; Patrick Maison; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

4.  Microsurgical therapy of pituitary adenomas.

Authors:  Pietro Mortini; Lina Raffaella Barzaghi; Luigi Albano; Pietro Panni; Marco Losa
Journal:  Endocrine       Date:  2017-10-24       Impact factor: 3.633

5.  High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.

Authors:  Andrea Giustina; Stefania Bonadonna; Giovanna Bugari; Annamaria Colao; Renato Cozzi; Salvatore Cannavo; Laura de Marinis; Ettore Degli Uberti; Fausto Bogazzi; Gherardo Mazziotti; Francesco Minuto; Marcella Montini; Ezio Ghigo
Journal:  Eur J Endocrinol       Date:  2009-05-22       Impact factor: 6.664

6.  Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

Authors:  Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers
Journal:  Endocr Relat Cancer       Date:  2017-07-21       Impact factor: 5.678

7.  AcroVoice: eliciting the patients' perspective on acromegaly disease activity.

Authors:  Yanina Jackson; Emuella Flood; Stephanie Rhoten; Ellen M Janssen; Mark Lundie
Journal:  Pituitary       Date:  2019-02       Impact factor: 4.107

8.  Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study.

Authors:  Andrea Giustina; Marcello D Bronstein; Philippe Chanson; Stephan Petersenn; Felipe F Casanueva; Caroline Sert; Aude Houchard; Shlomo Melmed
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 9.  A Consensus Statement on acromegaly therapeutic outcomes.

Authors:  Shlomo Melmed; Marcello D Bronstein; Philippe Chanson; Anne Klibanski; Felipe F Casanueva; John A H Wass; Christian J Strasburger; Anton Luger; David R Clemmons; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2018-09       Impact factor: 43.330

10.  Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly.

Authors:  Aart J van der Lely; Roy Gomez; Andreas Pleil; Xavier Badia; Thierry Brue; Michael Buchfelder; Pia Burman; David Clemmons; Ezio Ghigo; Jens Otto Lunde Jørgensen; Anton Luger; Joli van der Lans-Bussemaker; Susan M Webb; Christian J Strasburger
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107
View more
  42 in total

1.  Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length.

Authors:  Francesco Cocchiara; Claudia Campana; Federica Nista; Giuliana Corica; Marco Ceraudo; Angelo Milioto; Diego Criminelli Rossi; Gianluigi Zona; Diego Ferone; Federico Gatto
Journal:  Pituitary       Date:  2021-11-10       Impact factor: 4.107

2.  Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly.

Authors:  Sabrina Chiloiro; Denise Costa; Rosa Lauretta; Valeria Mercuri; Emilia Sbardella; Irene Samperi; Marialuisa Appetecchia; Antonio Bianchi; Antonella Giampietro; Patrizia Gargiulo; Andrea M Isidori; Maurizio Poggi; Alfredo Pontecorvi; Laura De Marinis
Journal:  Endocrine       Date:  2022-08-20       Impact factor: 3.925

3.  Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Authors:  Yifan Tang; Tao Xie; Silin Wu; Qiaoqiao Yang; Tengfei Liu; Chen Li; Shuang Liu; Zhiyong Shao; Xiaobiao Zhang
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

4.  Pituitary adenoma…nomen omen?

Authors:  Andrea Giustina
Journal:  Endocrine       Date:  2021-06-10       Impact factor: 3.633

Review 5.  Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly.

Authors:  Giovanni Tulipano; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2021-04-05       Impact factor: 6.514

6.  Echocardiographic findings in acromegaly: prevalence of concentric left ventricular remodeling in a large single-center cohort.

Authors:  J M Hinojosa-Amaya; E V Varlamov; C G Yedinak; J S Cetas; S McCartney; S Banskota; M Fleseriu
Journal:  J Endocrinol Invest       Date:  2021-04-24       Impact factor: 4.256

7.  Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.

Authors:  Federica Nista; Giuliana Corica; Lara Castelletti; Keyvan Khorrami; Claudia Campana; Francesco Cocchiara; Gabriele Zoppoli; Alessandro Prior; Diego Criminelli Rossi; Gianluigi Zona; Diego Ferone; Federico Gatto
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-07       Impact factor: 5.555

8.  Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.

Authors:  Júnia R O L Schweizer; Katharina Schilbach; Michael Haenelt; Alexandre V Giannetti; Mariana F Bizzi; Beatriz S Soares; Eduardo Paulino; Jochen Schopohl; Sylvère Störmann; Antônio Ribeiro-Oliveira; Martin Bidlingmaier
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

9.  Complication avoidance protocols in endoscopic pituitary adenoma surgery: a retrospective cohort study in 514 patients.

Authors:  Jai Deep Thakur; Alex Corlin; Regin Jay Mallari; Samantha Yawitz; Amalia Eisenberg; Walavan Sivakumar; Chester Griffiths; Ricardo L Carrau; Sarah Rettinger; Pejman Cohan; Howard Krauss; Katherine A Araque; Garni Barkhoudarian; Daniel F Kelly
Journal:  Pituitary       Date:  2021-07-02       Impact factor: 4.107

10.  Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection.

Authors:  Hani J Marcus; Danyal Z Khan; Anouk Borg; Michael Buchfelder; Justin S Cetas; Justin W Collins; Neil L Dorward; Maria Fleseriu; Mark Gurnell; Mohsen Javadpour; Pamela S Jones; Chan Hee Koh; Hugo Layard Horsfall; Adam N Mamelak; Pietro Mortini; William Muirhead; Nelson M Oyesiku; Theodore H Schwartz; Saurabh Sinha; Danail Stoyanov; Luis V Syro; Georgios Tsermoulas; Adam Williams; Mark J Winder; Gabriel Zada; Edward R Laws
Journal:  Pituitary       Date:  2021-07-06       Impact factor: 4.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.